Guillain-Barré Syndrome Treatment Guidelines

Initial Management and Diagnosis

Admit patients with Guillain-Barré Syndrome to a monitored unit with rapid ICU transfer capability because GBS can progress rapidly to respiratory failure, which occurs in approximately 25% of patients 1, 2
Obtain immediate neurology consultation to confirm diagnosis and guide treatment 1
Begin frequent respiratory function monitoring using vital capacity, maximum inspiratory pressure, and maximum expiratory pressure 1, 2
Apply the "20/30/40 rule" to assess respiratory failure risk: patient is at risk if vital capacity <20 mL/kg, maximum inspiratory pressure <30 cmH₂O, or maximum expiratory pressure <40 cmH₂O 2
Perform MRI of spine with and without contrast to rule out compressive lesions and evaluate for nerve root enhancement 3, 4, 1
Conduct lumbar puncture for cerebrospinal fluid analysis, which typically shows elevated protein 3, 4, 1
Order electrodiagnostic studies to evaluate polyneuropathy 1
Consider anti-ganglioside antibody testing, particularly anti-GQ1b if Miller Fisher syndrome is suspected 3, 4

The American College of Neurology recommends intravenous immunoglobulin (IVIg) as the preferred first-line treatment over plasma exchange due to easier administration, wider availability, and higher completion rates 2
IVIg dosing: 0.4 g/kg/day for 5 consecutive days (total 2 g/kg) 1, 2
Initiate IVIg within 2 weeks of symptom onset for patients unable to walk unaided 2
The 5-day IVIg regimen is preferred over shorter regimens because treatment-related fluctuations occur more frequently with abbreviated courses 1

Perform frequent neurological examinations to track disease progression 1, 2
Monitor for autonomic dysfunction via electrocardiography, heart rate, blood pressure, and bowel/bladder function 1, 2
Assess for pain and provide nonopioid management of neuropathic pain 3, 4
Use the modified Erasmus GBS Respiratory Insufficiency Score to calculate probability of requiring mechanical ventilation 2
Perform frequent pulmonary function assessments 3, 4

Do not give corticosteroids alone as they are ineffective and may worsen outcomes 2
Do not routinely give a second course of IVIg to patients with poor prognosis, as this increases serious adverse events without proven benefit 2
Avoid medications that worsen neuromuscular function: β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolides 3, 4, 2

Approximately 40% of patients do not improve in the first 4 weeks following treatment, which does not necessarily indicate treatment failure 2
Treatment-related fluctuations occur in 6-10% of patients within 2 months of initial improvement; repeating the full IVIg course is common practice for treatment-related fluctuations 2
About 80% of patients regain walking ability at 6 months, though 20% remain unable to walk 2
Mortality is 3-10%, most commonly from cardiovascular and respiratory complications 1, 2